Clinical Trials Browser

Adrenocortical Carcinoma

Sinonasal Squamous Cell Carcinoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Basal Cell, Skin Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Renal Cell

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

HPV-Related Squamous Cell Carcinoma

Carcinoma, Renal Cell

Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck

Rectal Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Renal Cell

Squamous Cell Carcinoma of Head and Neck

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Advanced Squamous Non-Small Cell Lung Cancer

Solid Tumors

Urinary Bladder Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Mesothelioma, Malignant

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Melanoma, Skin Neoplasms

Carcinoma, Non-Small-Cell Lung

Colonic Neoplasms

Skin Neoplasms, Carcinoma, Merkel Cell

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

Carcinoma, Squamous Cell

Neoplasm Metastasis

Resectable Non-small Cell Lung Cancer

SMARCB1-Deficient Malignancies

Cutaneous Squamous Cell Carcinoma

Clinical Trials

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

I-SPY

RAD-IO

CEMI-first

TOP 2301: Neoadjuvant Chemo for NSCLC

A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma

Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1

MINIMA

LAG-BOOST

Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

GAP Cemi

N-PLANC

ICARS

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

CECYDE

Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

SPORADIC

LAG-MAPS

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

META-1

NACho

NeoMatryx

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

THIO Sequenced With Cemiplimab in Advanced NSCLC

A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

SWITCH

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma